drugset / Trial / NCT00422981
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
Timeline
- Start
- 2007-01
- Primary completion
- 2008-01
- Completion
- 2008-01
Publications
- Gozes I, Blatt J, Lobyntseva A. Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease. Transl Psychiatry. 2024 Oct 2;14(1):412. doi: 10.1038/s41398-024-03118-0.
- Morimoto BH, Schmechel D, Hirman J, Blackwell A, Keith J, Gold M; AL-108-211 Study. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35(5-6):325-36. doi: 10.1159/000348347. Epub 2013 Apr 13.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | davunetide | Protein / enzyme biologic | 5 mg | Intranasal |
| Comparator | davunetide | Protein / enzyme biologic | 15 mg | Intranasal |